APA (7th ed.) Citation

Berinstein, N., Bence-Bruckler, I., Forward, N., Laneuville, P., Mangel, J., Stewart, D., . . . Conlon, R. (2020). 356 Baseline PD-L1 expression and tumor immune infiltration is associated with clinical response in patients with r/r DLBCL treated with DPX-Survivac, low-dose cyclophosphamide and pembrolizumab. Journal for immunotherapy of cancer, 8(Suppl 3), A381. https://doi.org/10.1136/jitc-2020-SITC2020.0356

Chicago Style (17th ed.) Citation

Berinstein, Neil, et al. "356 Baseline PD-L1 Expression and Tumor Immune Infiltration Is Associated with Clinical Response in Patients with R/r DLBCL Treated with DPX-Survivac, Low-dose Cyclophosphamide and Pembrolizumab." Journal for Immunotherapy of Cancer 8, no. Suppl 3 (2020): A381. https://doi.org/10.1136/jitc-2020-SITC2020.0356.

MLA (9th ed.) Citation

Berinstein, Neil, et al. "356 Baseline PD-L1 Expression and Tumor Immune Infiltration Is Associated with Clinical Response in Patients with R/r DLBCL Treated with DPX-Survivac, Low-dose Cyclophosphamide and Pembrolizumab." Journal for Immunotherapy of Cancer, vol. 8, no. Suppl 3, 2020, p. A381, https://doi.org/10.1136/jitc-2020-SITC2020.0356.